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Gentamicin  beads  are  used  for  musculoskeletal  infections. 
Gentamicin is released gradually from the beads, and high gen-
tamicin concentrations are achieved only locally. Side effects 
of gentamicin are rarely to be expected with gentamicin beads 
since only low amounts of gentamicin are released from the 
beads, resulting in extremely low serum concentrations of the 
antibiotic (Septopal SPC, Wahlig et al. 1978, Walenkamp et al. 
1986). Only one case of prolonged raised gentamicin serum 
levels from gentamicin beads has been described to date, but 
no adverse effects were reported in that case (Walenkamp and 
Vree 1981). We present another case with ototoxicity also. 
Case
A 70-year-old man had a total knee replacement performed 
because of osteoarthritis. He had a history of atrial fibrillation, 
heart failure, mitral regurgitation, chronic obstructive pulmo-
nary disease, diabetes mellitus, and he had no known drug 
allergies. He had never complained of hearing loss.
The  postoperative  course  was  complicated  by  paralytic 
ileus, perforation of the small bowel, and acute renal failure 
(which resolved with continous veno-venous hemofiltration) 
for which intensive care was necessary from day 7 to day 18 
postoperatively. The patient was re-admitted to the intensive 
care unit from day 21 to 23, for bleeding complications. Hear-
ing loss, which reversed after a few days, was reported on day 
23, 11 days after a 400-mg single preoperative intravenous 
dose of gentamicin. The patient was admitted to the intensive 
care unit again—from day 64 to day 67—for renal failure 
caused by fluid depletion, which resolved after filling. On day 
112, the patient was admitted to the intensive care unit for 
respiratory insufficiency after surgery for partial small bowel 
resection. During this stay in intensive care, surgery for fascia 
dehiscence after laparotomy and surgery for multiple entero-
cutaneous fistulas were performed. A Staphylococcus aureus 
sepsis on day 157, caused by a purulent arthritis of the left 
hip that was diagnosed on day 161, was treated by arthrotomy 
drainage and irrigation with implantation of 120 gentamicin 
beads on day 162. A Girdlestone arthroplasty was performed 
on day 176 and the gentamicin beads were changed. At the 
time of implantation of the gentamicin beads and thereafter, 
the patient had a normal renal function (estimated MDRD of 
65 mL/min/1.73 m2, reference value > 60 mL/min/1.73 m2).
Medications  during  this  94-day  period  on  intensive  care 
included furosemide (20 mg i.v. twice daily initially, and later 
increased to 500 mg every 24 hours), ceftazidim (1,000 mg 
i.v. 3 times daily), flucloxacillin (continuously, 12 g i.v. daily), 
ciprofloxacin (400 mg i.v. twice daily), potassium chloride 
(i.v. and per os), metoclopramide (10 mg i.v. 3 times daily), 
buprenorphine (70 mcg/h transdermal patch every 3 days),   
midazolam (i.v.), dalteparin (7,500 IE subcutaneously twice 
daily), fentanyl (i.v.), olanzapine (5 mg per os, initially twice 
daily but later reduced to once daily), acenocoumarol (per os), 
norepinephrine (i.v.), gabapentin (300 mg per os, initially once 
daily but later increased to 3 times daily) and spironolactone 
(25 mg per os once daily).
10 days after implantation of the gentamicin beads (day 
172), the patient complained about sudden severe hearing loss 
and the gentamicin level was 0.7 mg/L. The reference value 
for trough gentamicin levels after gentamicin infusion is < 0.5 
mg/L. The levels that followed were: 0.9 mg/L (day 179), 0.9 
mg/L (day 181), 1.0 mg/L (day 187), 0.7 mg/L (day 194), and 
0.4 mg/L (day 201). Gentamicin concentrations were detect-
able for 4 weeks, and were above the reference value for 3 
weeks (Figure). During this period, the patient had not been 
treated with gentamicin through any other route. He died in the 
intensive care unit on day 216. No obduction was performed. 
Discussion
Pharmacokinetics
Gentamicin-polymethylmethacrylate  (gentamicin-PMMA) 
beads are balls of bone cement that release gentamicin locally 
at initially high concentrations, followed by a period of con-
stant  release  for  up  to  about  80  days.  Systemically,  only 
extremely low concentrations are detectable: generally, serum 
gentamicin levels remain below 0.1 mg/L. In daily clinical 
practice, serum levels of 0.4 mg/L and lower can be regarded 
as immeasurable. The blood-bone barrier, which gives diffi-
culty in achieving therapeutic concentrations locally with sys-
temic administration, prevents high serum concentrations with 
local therapy (Walenkamp et al. 1986). Renal clearance of 
gentamicin mainly depends on glomerular filtration, with only 
a small amount of tubular reabsorption (Chiu et al. 1976).Acta Orthopaedica 2009; 80 (6): 734–736  735
Studies have been published on the pharmacokinetics of gen-
tamicin beads, but with a relatively small number of patients. 
Gentamicin levels measured in 5 patients with 48–360 beads 
were measurable only in 1 patient (with 360 beads implanted). 
After a peak level of 1.8 mg/L on day 1, a plateau level of 0.4 
mg/L was reached. This patient had a plasma creatinine level 
of 73 μmol/L (reference value 60–110 μmol/L). The release 
and excretion depended on vascularization of the surround-
ing tissues: excretion was faster when beads were placed in 
muscle tissue than when they were placed in sclerotic bone 
tissue (Walenkamp et al. 1986). The largest study involved 
41 patients. Only traces of gentamicin were found, even in 
patients with the largest numbers (80–180) of beads (Wahlig 
et al. 1978). The only case report of raised gentamicin serum 
levels  with  gentamicin  beads  decribes  the  implantation  of 
150 beads in a patient with creatinine clearance of 1 mL/min 
(reference value > 60 mL/min). The gentamicin level in this 
patient was 3 mg/L and decreased to 2 mg/L. The duration of 
raised gentamicin levels was not described in this case report 
(Walenkamp and Vree 1981). No adverse effects have been 
reported with gentamicin beads.
In our case, the serum gentamicin levels were measurable for 
more then 3 weeks. This is unique; there have been no reports 
of gentamicin levels of this magnitude for such a long time 
and caused by gentamicin beads alone. Moreover, in our case 
there was no indication of renal failure during the period of 
raised gentamicin levels, and the amount of gentamicin beads 
implanted was lower than in the cases of raised gentamicin 
serum levels described above. The cause of the altered genta-
micin pharmacokinetics may have been an increased uptake 
through increased local blood flow at the site of the wound, or 
possibly an impaired blood-bone barrier.
Ototoxicity
All  aminoglycosides  can  damage  cochlear  and  vestibular 
organs.  Cochleotoxicity  presents  as  bilateral  sensorineural 
hearing  loss,  initially  affecting  the  high  frequencies.  Early 
toxicity often goes unnoticed, since the frequencies affected 
initially fall outside the range of speech (Rizzi and Hirose 
2007,  Seligmann  et  al.  1996).  Damage  then  progresses  to 
lower frequencies, including frequencies in the human speech 
range (Forge and Schacht 2000). Since gentamicin clearance 
from the inner ear is slow, ototoxicity may sometimes become 
manifest after some days or weeks (Bates et al. 2002). 
Aminoglycoside-induced  hearing  loss  is  permanent  in 
approximately half of all patients affected. It may occur by 
any administration route, but has not been described with gen-
tamicin beads (Seligmann et al. 1996). In 2 audiometric stud-
ies in patients with implanted gentamicin beads, no ototoxicity 
was found (Haydon et al. 1993, Walenkamp et al. 1987). Even 
though there is no clear association between ototoxicity and 
aminoglycoside levels, raised levels could increase the risk of 
ototoxicity (Rizzi and Hirose 2007). 
In our case, sudden bilateral hearing loss occurred ten days 
after implantation of the beads, and had progressed to fre-
quencies in the human speech range. The patient had previ-
ously experienced reversible hearing loss 12 days after a 400-
mg intravenous dose of gentamicin, and he may have been 
extremely sensitive to the ototoxic properties of gentamicin. 
Use of the Naranjo adverse drug reaction probability scale 
(Naranjo et al. 1981) indicates a probable relationship between 
hearing loss and gentamicin beads: this adverse reaction has 
previously been reported with gentamicin in the literature. The 
timeline of implantation was consistent with the appearance of 
the adverse effect. A rechallenge has led to hearing loss and 
toxic levels of gentamicin were found in serum. 
Risk factors that might possibly have been involved in our 
case were poor nutritional state, age, bacteremia, duration of 
measurable gentamicin serum levels of more then 10 days, 
or a genetic predisposition (Seligmann et al. 1996, Forge and 
Schacht 2000, Bates et al. 2002). Genetic predisposition was 
not evaluated in our patient. The combination with the loop 
diuretic furosemide may also have contributed, since this com-
bination may lead to total deafness—even under conditions in 
which neither drug alone causes a hearing deficit (Forge and 
Schacht 2000). The furosemide dose used to stimulate diuresis 
in our case was fairly high, but not unusually high.
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Systemic  gentamicin  concentrations  and  creatinine  concentrations. 
Total knee replacement was performed on day 1. On day 162, 120 
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